-
Phase 1
-
-
18+Age Range
-
12Locations
-
Recruiting
Recruiting
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Experimental: Part 1: Dose Escalation BMS-986497 (Monotherapy)
Experimental: Part 2, Cohort A: Dose Expansion BMS-986497 (Combination Therapy)
Experimental: Part 2, Cohort B: Dose Expansion BMS-986497 (Triple Combination Therapy)